Skip to content
Menu

Immunome, Inc. IMNM

Full chart Compare
Set alert

Price alert · IMNM

All alert types
16.61 USD -0.17 (-1.01%)

Regular-session close

16.61 0.00 0.00%

After hours · Nov 19, 4:39 PM ET

16.45 Day range 17.18
16.41 52-week range 30.06
YTD
-22.67%
1 year
-6.11%

5D -1.15 (-6.13%)

17.501818.5019TueWedThuFriMon17.61
Market cap
1.96B
EPS (ttm)
-2.63
Shares out
118.07M
Forward P/E
-6.41
YTD return
-22.67%
1-year return
-6.11%
50-day average
20.09
200-day average
22.08
Enterprise value
1.53B
Price / book
4.16
Volume
881.29K
Avg volume
1.36M
Open
16.80
Previous close
16.78
Day's range
16.45 – 17.18
52-week range
16.41 – 30.06
Beta
2.66
Analysts
Strong Buy
Price target
35.13 (+111.5%)
Earnings date
Mar 2, 2027

Key statistics

Free cash flow
-159.73M
Total cash
461.58M
Total debt
11.38M
Return on equity
-78.71%
Short % of float
15.92%

Fundamental scorecard

4 of 25 checks passed on IMNM’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IMNM Revenue — quarterly 0
IMNM Net income — quarterly -85.78M
IMNM EPS — quarterly -0.76

Earnings

IMNM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 2, 2027Dec 30, 2026-0.76———
Nov 9, 2026Sep 30, 2026-0.62174-0.76-0.14-22.24%
Aug 11, 2026Jun 30, 2026-0.51381-0.65-0.14-26.51%
May 12, 2026Mar 31, 2026-0.60-0.48+0.12+20.00%
Mar 3, 2026Dec 31, 2025-0.59017-0.75-0.16-27.08%
Nov 6, 2025Sep 30, 2025-0.57-0.65-0.08-14.04%

Upgrades / downgrades

IMNM analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026StifelmainHoldHold
Nov 10, 2026Piper SandlermainOverweightOverweight
Oct 27, 2026WedbushreitOutperformOutperform
Oct 16, 2026William Blairinit—Outperform
Oct 1, 2026Stifelinit—Hold
Sep 21, 2026Alliance Global Partnersinit—Buy

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
immunome.com

News

Your note

Sign in to keep a note on IMNM — it syncs with the Stock Master app.

Insider holders

IMNM insider holders
InsiderRelationLatest transactionDateShares held
BARCHAS ISAACDirectorSaleAug 11, 20260
BIENAIME JEAN-JACQUESDirectorPurchaseJun 4, 202643,415
HIGGINS JACKOfficerConversion of Exercise of derivative securitySep 10, 202659,250
HORN KINNEYOfficerConversion of Exercise of derivative securityAug 3, 20260
LECHLEIDER ROBERTOfficerStock Award(Grant)Jul 22, 202669,805
ROSETT MAXChief Financial OfficerStock Award(Grant)Jul 22, 2026101,287

Institution ownership

IMNM institution ownership
Holder% heldSharesValueReported
T. Rowe Price Investment Management, Inc.17.12%20,211,392335.71MSep 29, 2026
FMR, LLC14.43%17,036,641282.98MSep 29, 2026
Blackrock Inc.7.56%8,929,024148.31MSep 29, 2026
Wellington Management Group, LLP5.12%6,041,333100.35MSep 29, 2026
Driehaus Capital Management, LLC4.22%4,976,95082.67MSep 29, 2026
Vanguard Capital Management LLC4.13%4,882,13181.09MSep 29, 2026

Fund ownership

IMNM fund ownership
Holder% heldSharesValueReported
T. Rowe Price Small-Cap Stock Fund, Inc.6.08%7,179,563119.25MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund4.24%5,004,68483.13MSep 29, 2026
T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd.3.31%3,907,37864.90MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.14%3,703,46161.51MJul 30, 2026
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund3.13%3,692,94161.34MSep 29, 2026
TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust2.87%3,392,15156.34MJun 29, 2026